Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have described benzene ring derivatives acting as GABA-A receptor agonists reported to be useful for anesthesia and for the treatment of anxiety disorders, insomnia, depression, nausea and vomiting, migraine, convulsions, schizophrenia and epilepsy.

Researchers at China Pharmaceutical University and Chongqing Innovation Institute, China Pharmaceutical University have divulged ubiquitin C-terminal hydrolase 7 (USP7; HAUSP) inhibitors reported to be useful for the treatment of inflammatory disorders, infections and cancer.

Shaoxing City Youluofei Pharmaceutical Co. Ltd. has identified adenosine receptor ligands reported to be useful for the treatment of cancer, diabetes, pain, neuroinflammation, metabolic diseases, cardiovascular diseases, respiratory disorders and inflammatory disorders, among others.

Beijing Innocare Pharma Tech Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors and/or degradation inducers reported to be useful for the treatment of psoriasis, cancer, rheumatoid arthritis, asthma and more.

Insmed Inc. has described cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors reported to be useful for the treatment of cancer, liver injury, osteoarthritis, heart failure, inflammatory bowel disease, rheumatoid arthritis, bronchiectasis and chronic obstructive pulmonary disease, among others.

Guangdong Yinzhu Pharmaceutical Technology Co. Ltd. and Guangzhou Yinzhu Biomedical Technology Co. Ltd. have divulged triazole compounds reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis and inflammatory bowel disease.

Beijing Double-Crane Runchuang Technology Co. Ltd. has identified heterocyclic compounds reported to be useful for the treatment of cancer.

Sunrise Oncology (Hong Kong) Ltd. has synthesized molecular glues acting as GTPase KRAS (and/or its mutant)/RAF proto-oncogene serine/RAF1 interaction inhibitors reported to be useful for the treatment of cancer.

Guangzhou Diqi Pharmaceuticals Co. Ltd. has disclosed crystalline forms of rasagiline reported to be useful for the treatment of Parkinson’s disease.